New Delhi: The Union Health Ministry has decided not to include ivermectin medicine (antiparasitic drug) in the National Clinical Management Protocol for Covid-19 for the treatment of virus-infected patients.
The move comes after the Central government's National Task Force for Covid-19 and the health ministry's Joint Monitoring Group (JGM) chaired a meeting on Thursday to discuss if the anti-parasitic drug should be included in the national treatment guidelines or not.
A government official said, "Many states, for example--Uttar Pradesh, are utilizing the drug as off label for treatment purpose and also for prophylaxis use against Covid-19. Now, it has been decided not to recommend ivermectin medicine in the National Clinical Management Protocol for Covid-19 as there is not enough safety and efficacy evidence as per the randomized trials held across the world."
Ivermectin medicine is an inexpensive and safe drug that is used for the treatment of intestinational parasites and scabies.
Read also: CSIR-Centre developing proof of concept for Covid vaccine as part of Aurobindo Pharma pact
In the fight against Covid-19, the Union Health Ministry has approved the use of several drugs in the treatment of coronavirus with subject to conditions in the Clinical Management Protocol for Covid-19.
The Central government has already recommended the use of--remdesivir under "investigational therapies" only for restricted emergency use in moderate Covid-19 cases. Another drug called--tocilizumab is being used as off-label for the treatment of Covid patients. Meanwhile, anti-malaria drug hydroxychloroquine (HCQ) is being utilized in patients during the initial stage of infection.
Read also: Dr Harsh Vardhan launches CSIR partnered clinical trials website on repurposed Covid drugs